{"id":"a3799465-6142-4482-a199-e95e03442e40","kind":"news","code":"a3799465-6142-4482-a199-e95e03442e40","name":"iRegene raises RMB 210 million in Series C financing","nameBasis":"translated-title","summary":"On 2026-04-27, according to Xiniu Data, iRegene completed Series C financing, raising RMB 210 million. Investors were co-lead investor Nantongheyuanyihao Venture Capital Partnership (Limited Partnership), co-lead investor Xingze Capital. The company is a developer of chemically induced cell therapy drugs.","description":"","country":null,"category":null,"originalName":"睿健医药完成C轮融资，金额2.10亿人民币","eventDate":"2026-04-27T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-15T17:18:22.746Z","englishUpdatedAt":"2026-10-20T18:21:37.692Z","reviewedAt":"2026-10-20T18:21:37.692Z","snapshotAt":"2026-10-20T18:19:32.670Z","sourceHash":"aaa671244583d81a4647ac15cc31ee8ac312d48dda833fda09dbfe552cf76508","companyId":"c6f40f74-5248-4720-8404-fd1e03022e90","foundedYear":null,"logoUrl":null,"originalText":"2026年4月27日，据烯牛数据报道，睿健医药完成C轮融资，金额2.10亿人民币。投资方为南通合远壹号创业投资合伙企业（有限合伙）、杏泽资本领投。该公司为化学诱导细胞治疗药物研发商。","sources":[],"related":[{"id":"0717c149-36b2-49de-8798-19c308e61287","kind":"institutions","code":"UB-I10624","name":"Nantongheyuanyihao Venture Capital Partnership","nameBasis":"transliterated","summary":"","description":"","country":null,"category":null,"originalName":"南通合远壹号创业投资合伙企业","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T17:24:18.434Z","englishUpdatedAt":"2026-10-15T18:35:34.833Z","reviewedAt":"2026-10-15T18:35:34.833Z","snapshotAt":"2026-10-15T18:31:23.182Z","sourceHash":"b8e13a39f3e7e2bf71f919e458c6eee1ca694912ad26ea02059d7f4b2f27adb0","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/nantongheyuanyihao-venture-capital-partnership"},{"id":"8727eb8f-30c3-4e56-856c-24dfb40e9978","kind":"institutions","code":"UB-I1304","name":"Xingze Capital","nameBasis":"transliterated","summary":"Xingze Capital is an early-stage investment firm focused on healthcare.","description":"Xingze Capital is an early-stage investment firm focused on healthcare.","country":null,"category":null,"originalName":"杏泽资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:04:26.662Z","englishUpdatedAt":"2026-10-15T20:40:58.142Z","reviewedAt":"2026-10-15T20:40:58.142Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"3956ac0ad7e2c7dd163b34e61512cae95ff66d6a199416f4764163dd3ee97848","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/xingze-capital"},{"id":"c6f40f74-5248-4720-8404-fd1e03022e90","kind":"companies","code":"UB-C5987","name":"iRegene","nameBasis":"source-english","summary":"AI and chemically induced cell drug research and development.","description":"","country":"China","category":null,"originalName":"睿健医药","eventDate":null,"website":"https://www.iregene.com/","sourceUpdatedAt":"2026-10-08T00:00:00.000Z","englishUpdatedAt":"2026-10-20T18:26:36.154Z","reviewedAt":"2026-10-20T18:26:36.154Z","snapshotAt":"2026-10-20T18:05:01.520Z","sourceHash":"4f1558709e5410f70940856de858bdad558b4dea9749771117809729b847f483","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/companies/UB-C5987"}],"path":"/news/a3799465-6142-4482-a199-e95e03442e40","structured":{"city":null,"country":null,"location":null,"role":null,"category":null,"company":{"name":"iRegene","path":"/companies/UB-C5987"}},"canonical":"https://uniquebase.ai/news/a3799465-6142-4482-a199-e95e03442e40"}